Posted by Michael Wonder on 27 Jun 2024
Verona Pharma announces US FDA approval of Ohtuvayre (ensifentrine)
26 June 2024 - First inhaled chronic obstructive pulmonary disease treatment providing bronchodilation and non-steroidal anti-inflammatory effects.
Verona Pharma announces the US FDA approved Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease in adult patients.
